P108: Analysis Of Postoperative Cytokine Adsorber Therapy (Cytosorbentstm Inc Cytosorb®) In Patients With Condition After Implantation Of A Mechanical Left Ventricular Assist Device (Medtronic Heartwaretm HVADTM System)

Abstract

Purpose: Ventricular assist devices (VADs) improve heart failure outcomes, yet the challenge of reducing bleeding, stroke, and infection persists. Biomarkers related to these adverse events were evaluated with a next-generation, totally magnetically suspended (TMS) VAD in comparison to other blood pumps. Method: Bovine whole blood or human plasma was circulated through benchtop flow loops with an Abbott CentriMag (CM) or HeartMate II (HMII), or a CH Biomedical USA BrioVAD (N = 5 tests). Flows were maintained at 4.5 L/min against an afterload of 75 mmHg. Samples were collected hourly for 6 hours. Plasma free hemoglobin was measured by spectroscopy. Normalized index of hemolysis (NIH) was calculated as described in ASTM F1841-19. VWF function (VWF:CB/Ag) was quantified using VWF:CB and VWF:Ag assay kits; VWF multimer distribution was determined using agarose-gel electrophoresis and in-gel immunofluorescent staining. Statistical significance was determined using an ANOVA (NIH) or regression analysis (VWF:CB/Ag) followed by a post-hoc Tukey test for significance between specific devices. Results: The CM and BrioVAD exhibited significantly lower hemolysis than the HMII